Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05929885RecruitingPhase 2
Genotype-guided chemo for metastatic pancreatic cancer
This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.
SingaporeAges 21–99 - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT05805371RecruitingPhase 1
PSCA CAR-T cells with or without radiation for prostate cancer
This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.
Duarte, CaliforniaAges 18 years+ - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT05727176RecruitingPhase 2
Futibatinib for advanced bile duct cancer with FGFR2 changes
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT05651828RecruitingEarly Phase 1
Tested adaptive dosing of vismodegib for advanced skin cancer
This trial tests an adaptive (adjusted) dosing plan using vismodegib for people with advanced basal cell carcinoma. It may help control the cancer while balancing side effects, and your team will closely monitor how your tumors respond.
Tampa, FloridaAges 18 years+ - NCT05655949RecruitingPhase 2
Y-90 radiation plus immunotherapy and chemo for bile duct cancer
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Boston, MassachusettsAges 18 years+ - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Kingman, ArizonaAges 18 years+ - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05526443Recruiting
Registry study for advanced pancreatic cancer treatment patterns
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Graz, StyriaAges 18 years+ - NCT05524584RecruitingPhase 2
Anastrozole, fulvestrant, and abemaciclib for hormone-positive breast cancer
This trial tests whether combining three medicines can better control hormone-receptor–positive, HER2-negative metastatic breast cancer that cannot be cured with surgery or radiation. It may help shrink tumors and slow disease growth compared with standard hormone therapy approaches.
Orange, CaliforniaAges 18 years+ - NCT05472948RecruitingPhase 2
Testing surufatinib plus immunotherapy with capecitabine for bowel cancer
This Phase 2 study tests a combination of anti-cancer drugs (surufatinib, immunotherapy, and capecitabine) to treat cancer that has spread to other parts of the body. It’s for people whose small intestine or appendix adenocarcinoma has progressed after earlier treatment, aiming to shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18–70 - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT05396872Recruiting
Decision-making study about gene testing for advanced prostate cancer
This study looks at how Veterans with advanced prostate cancer make decisions about gene testing and possible targeted treatments, and how patients and caregivers understand the information. It may help by improving decision support for people facing germline and tumor testing choices.
San Francisco, CaliforniaAges 18 years+ - NCT05398484RecruitingPhase 2/Phase 3
Psilocybin therapy for advanced cancer-related anxiety
This trial studies whether psilocybin (with support and therapy) can reduce anxiety in people with advanced cancer. It may help with distress and quality of life, while the study team monitors safety closely.
Aurora, ColoradoAges 21–100 - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05276310RecruitingPhase 1
Study of IMC-002 in advanced cancer
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Goyang-siAges 19 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT05257590RecruitingPhase 2
CVM-1118 plus nivolumab for advanced liver cancer
This Phase 2 trial tests whether CVM-1118 given with nivolumab can help people with advanced, unresectable hepatocellular carcinoma (a type of liver cancer) that can’t be cured with surgery. It’s for patients whose cancer has worsened after earlier cancer medicines or treatments.
Kaohsiung CityAges 18 years+ - NCT05226169RecruitingPhase 3
Iron medicine plus standard therapy for advanced stomach cancer
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
SeoulAges 19 years+ - NCT05112991RecruitingPhase 2
Check whether envafolimab plus lenvatinib helps advanced uterine cancer
This Phase 2 trial tests whether envafolimab alone or combined with lenvatinib can slow or shrink advanced endometrial (uterine) cancer. It’s for people whose cancer has grown again or spread and who didn’t do well with standard platinum chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Targeted therapy for advanced lung cancer with EGFR or HER2 changes
This trial tests a new targeted drug for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2). The drug may slow cancer growth and help you live longer.
Gilbert, ArizonaAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,336 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.